We are live on ! Find out more
AGIO icon

Agios Pharmaceuticals
AGIO

66 hedge funds and large institutions have $420M invested in Agios Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 28 increasing their positions, 17 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

73% more capital invested

Capital invested by funds: $242M → $420M (+$178M)

65% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 17

8% less funds holding

Funds holding: 72 → 66 (-6)

30% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 20

Holders
66
Holders Change
-6
Holders Change %
-8.33%
% of All Funds
1.92%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.06%
New
14
Increased
28
Reduced
17
Closed
20
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BFA
BlackRock Fund Advisors
California
+$8.04M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$5.94M
3
Jennison Associates
Jennison Associates
New York
+$3.01M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$2.85M
5
ClearBridge Investments
ClearBridge Investments
New York
+$2.19M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$6.09M
2
PHS
PFM Health Sciences
California
-$5.78M
3
DM
Deerfield Management
New York
-$4.22M
4
Franklin Resources
Franklin Resources
California
-$2.91M
5
WMSA
Weiss Multi-Strategy Advisers
New York
-$2.25M
Name Holding Trade Value Shares
Change 		Change in
Stake
Axa
26
Axa
France
$1.42M +$1.36M +59,473 New
TG
27
TCW Group
California
$1.28M -$395K -17,312 -24%
Principal Financial Group
28
Principal Financial Group
Iowa
$972K +$13.7K +600 +2%
Geode Capital Management
29
Geode Capital Management
Massachusetts
$919K +$12.7K +558 +1%
WSA
30
Wall Street Associates
California
$897K -$55.2K -2,420 -6%
VAM
31
Visium Asset Management
New York
$838K -$13.7K -600 -2%
JP Morgan Chase
32
JP Morgan Chase
New York
$773K +$36.3K +1,591 +5%
CBOA
33
Commonwealth Bank of Australia
Australia
$719K +$362K +15,877 +112%
TCIM
34
TIAA CREF Investment Management
New York
$671K +$253K +11,100 +66%
TI
35
Turner Investments
Pennsylvania
$668K -$1.06M -46,330 -62%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$662K +$185K +8,128 +42%
TRSOTSOK
37
Teachers Retirement System of the State of Kentucky
Kentucky
$635K +$199K +8,750 +49%
BG
38
BlackRock Group
United Kingdom
$546K -$18.9K -829 -4%
NFA
39
Nationwide Fund Advisors
Ohio
$517K +$133K +5,815 +37%
BIM
40
BlackRock Investment Management
Delaware
$452K -$2.73K -120 -0.6%
MWNA
41
Marshall Wace North America
New York
$361K -$60.6K -2,657 -15%
Charles Schwab
42
Charles Schwab
California
$353K +$9.85K +432 +3%
ProShare Advisors
43
ProShare Advisors
Maryland
$339K +$323K +14,172 New
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$297K +$59.3K +2,600 +27%
CS
45
Credit Suisse
Switzerland
$267K -$29.9K -1,313 -11%
Goldman Sachs
46
Goldman Sachs
New York
$259K +$246K +10,812 New
WJA
47
Williams Jones & Associates
New York
$245K +$234K +10,250 New
TA
48
Teachers Advisors
New York
$228K – – –
Citigroup
49
Citigroup
New York
$180K +$148K +6,509 +651%
Deutsche Bank
50
Deutsche Bank
Germany
$177K -$123K -5,414 -42%
1
2
3 4

AGIO Hedge Fund Activity: Q4 2013 in Review

66 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q4 2013, worth a combined $420M — up 73% from $242M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of AGIO and 14 opened new positions — a net loss of 6 holders — while 17 trimmed existing stakes and 28 added.

The largest buyer was BlackRock Fund Advisors, adding an estimated $8.04M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $6.09M sold.

  • 66 institutional investors held Agios Pharmaceuticals (AGIO) as of Q4 2013, down from 72 in Q3 2013.
  • Funds reported $420M of Agios Pharmaceuticals stock for Q4 2013, up 73% quarter-over-quarter.
  • 14 funds opened new Agios Pharmaceuticals positions in Q4 2013 and 20 closed out, a net change of -6 holders.
  • The largest Agios Pharmaceuticals buyer in Q4 2013 was BlackRock Fund Advisors, an estimated $8.04M added.
  • The largest Agios Pharmaceuticals seller in Q4 2013 was T. Rowe Price Associates, an estimated $6.09M sold.

Based on aggregated 13F filings for Q4 2013.